By Maddie Sorenson
Integra Lifesciences Holdings Corp (NASDAQ:IART) was upgraded by Zacks from a “sell” rating to a “hold” rating in a research note issued on Monday, ARN reports.
According to Zacks, “We are impressed with Integra’s second-quarter 2015 results which squarely beat the Zacks Consensus Estimate. However, foreign currency fluctuations continued to adversely affect Integra’s international business
. Nevertheless, management believes strong execution within Integra’s regenerative product lines, including dural repair and skin, resulted in the better-than-expected second quarter. We believe, Integra’s decision to spin off its loss making spine segment SeaSpine is expected to prove beneficial for Integra’s growth. It will help Integra to invest more in top-line growth initiatives, allowing healthier balance sheet. Strategic acquisitions like MetaSurg, MicroFrance and TEI are also expected to add values. However, Integra’s declined 2015 guidance concerns us.”
IART has been the topic of a number of other reports. Oppenheimer set a $76.00 price target on Integra Lifesciences Holdings Corp and gave the stock a “buy” rating in a research reporton Monday, June 1st. Piper Jaffray reaffirmed a “buy” rating on shares of Integra Lifesciences Holdings Corp in a research note on Tuesday, August 4th. Raymond James upgraded Integra Lifesciences Holdings Corp from a “market perform” rating to an “outperform” rating in a research report on Wednesday, July 29th. Lake Street Capital dropped their target price on Integra Lifesciences Holdings Corp from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Wednesday, August 26th. Finally, Jefferies Group reiterated a “buy” rating and issued a $78.00 price objective (up previously from $67.00) on shares of Integra Lifesciences Holdings Corp in a report on Monday, July 6th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $71.33.
